In silico analysis of Abrus precatorius L. as a potential agonist of PPARγ : A novel approach to the treatment of diabetes

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2025 | Volume : 03 | 02 | Page :
    By

    Grace R. Michael*,

  1. Intern, Department of Bioinformatics, BioNome,, Karnataka, India

Abstract

Diabetes mellitus is a chronic disorder that is characterized by a lack of insulin secretion by the pancreas or a defect in insulin action, or both. If diabetes is not controlled, over time it can cause damage to blood vessels and nerves, leading to life-threatening complications such as, kidney damage, heart disease and vision impairment. It can also weaken the immune system, making patients more prone to infection. Although treatments for diabetes has improved over the past few decades, mortality rates due to diabetes and its complications have been on the rise. Moreover, some hyperglycemic agents have been shown to induce irreversible side effects. Therefore, there is an urgent need to explore alternative therapeutic treatments to combat this disease. Peroxisome proliferator-activated receptor gamma (PPARγ) is an important protein that helps regulate glucose levels in the blood. This study explores the potential modulation of PPARγ by phytochemical compounds. In many countries including India, medicinal plants have been used as anti-diabetic agents. Abrus precatorius Linn is an important herb commonly known as rosary pea and abundantly found throughout India. A.precatorius can be used to treat a variety of diseases as various parts of the plants have different pharmacological activity, such as anti-diabetic, anti-oxidative, anti- inflammatory, anti-microbial and neuro-protective effects. The phytochemicals were extracted from the Indian Medicinal Plants, Phytochemistry and Therapeutics(IMPPAT). PyRx, an in-silico tool was then used to perform molecular docking simulations in order to find the lead compounds. The phytochemical compounds kaempferol, carvacrol, abrine, thymol methyl ether, and thymol which had the highest binding affinities with PPARγ were selected for further in silico analysis and pharmacological evalution was carried out on the basis of ADMET properties, which was performed in ADMETlab. The compound kaempferol showed the highest binding affinity with PPARγ. Its molecular interaction with PPARγ was captured on Biovia Discovery Studio Visualizer.

Keywords: Diabetes mellitus, Abrus precatorius L., Peroxisome proliferator-activated receptor gamma (PPARγ), bioinformatics, molecular docking, PyRx, IMPPAT database, Biovia, kaempferol.

How to cite this article:
Grace R. Michael*. In silico analysis of Abrus precatorius L. as a potential agonist of PPARγ : A novel approach to the treatment of diabetes. International Journal of Molecular Biotechnological Research. 2025; 03(02):-.
How to cite this URL:
Grace R. Michael*. In silico analysis of Abrus precatorius L. as a potential agonist of PPARγ : A novel approach to the treatment of diabetes. International Journal of Molecular Biotechnological Research. 2025; 03(02):-. Available from: https://journals.stmjournals.com/ijmbr/article=2025/view=228125


References

1. Wilcox G. Insulin and insulin resistance. Clin Biochem Rev. 2005 May;26(2):19-39. PMID: 16278749; PMCID: PMC1204764.

2. Shendurse, A. M., and C. D. Khedkar. “Glucose: properties and analysis.” Encyclopedia of food and health 3 (2016): 239-247.

3. Bentley Cheatham, C. Ronald Kahn, Insulin Action and the Insulin Signaling Network, Endocrine Reviews, Volume 16, Issue 2, 1 April 1995, Pages 117–142, https://doi.org/10.1210/edrv-16-2-117

4. International Diabetes Federation.
IDF Diabetes Atlas, 11th edn. Brussels,
Belgium: 2025. Available at: https://diabetesatlas.org

5. Jay S. Skyler, George L. Bakris, Ezio Bonifacio, Tamara Darsow, Robert H. Eckel, Leif Groop, Per-Henrik Groop, Yehuda Handelsman, Richard A. Insel, Chantal Mathieu, Allison T. McElvaine, Jerry P. Palmer, Alberto Pugliese, Desmond A. Schatz, Jay M. Sosenko, John P.H. Wilding, Robert E. Ratner; Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes 1 February 2017; 66 (2): 241–255. https://doi.org/10.2337/db16-0806

6. Chaudhury A, Duvoor C, Reddy Dendi VS, Kraleti S, Chada A, Ravilla R, Marco A, Shekhawat NS, Montales MT, Kuriakose K, Sasapu A, Beebe A, Patil N, Musham CK, Lohani GP and Mirza W (2017) Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. Front. Endocrinol. 8:6. doi: 10.3389/fendo.2017.00006

7. Ekor M (2014) The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front. Pharmacol. 4:177. doi: 10.3389/fphar.2013.00177

8. Gordon A, Buch Z, Baute V, Coeytaux R. Use of Ayurveda in the Treatment of Type 2 Diabetes Mellitus. Global Advances in Health and Medicine. 2019;8. doi:10.1177/2164956119861094

9. Dafar, S., M. R., B., A. M., N., D. P., D., & S. S., R. (2023). A Review on Phytochemical and Pharmacological Study of Herbal Medicinal Plant: Abrus precatorious. International Journal of Newgen Research in Pharmacy & Healthcare, 1(2), 161–173. https://doi.org/10.61554/ijnrph.v1i2.2023.31

10. Huiqin Qian, Lu Wang, Yanling Li, Bailing Wang, Chunyan Li, Like Fang, Lijie Tang, The traditional uses, phytochemistry and pharmacology of Abrus precatorius L.: A comprehensive review, Journal of Ethnopharmacology, Volume 296,2022,115463,ISSN 0378 8741, https://doi.org/10.1016/j.jep.2022.115463.

11. Garaniya, Narendra, and Atul Bapodra. “Ethno botanical and Phytophrmacological potential of Abrus precatorius L.: A review.” Asian Pacific journal of tropical biomedicine 4 (2014): S27-S34

12. Carvalho, M.V.d.; Gonçalves-de-Albuquerque, C.F.; Silva, A.R. PPAR Gamma: From Definition to Molecular Targets and Therapy of Lung Diseases. Int. J. Mol. Sci. 2021, 22, 805. https://doi.org/10.3390/ijms22020805

13. Han, L., Shen, W. J., Bittner, S., Kraemer, F. B., & Azhar, S. (2017). PPARs: Regulators of Metabolism and As Therapeutic Targets in Cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ. Future Cardiology, 13(3), 279–296. https://doi.org/10.2217/fca-2017-0019

14. Agha Zeeshan Mirza, Ismail I. Althagafi, Hina Shamshad,Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications,European Journal of Medicinal Chemistry,Volume 166,2019,Pages 502- 513,ISSN02235234,https://doi.org/10.1016/j.ejmech.2019.01.067.(https://www.scienced irect.com/science/article/pii/S022352341930087X)

15. Wang L, Waltenberger B, Pferschy-Wenzig EM, Blunder M, Liu X, Malainer C, Blazevic T, Schwaiger S, Rollinger JM, Heiss EH, Schuster D, Kopp B, Bauer R, Stuppner H, Dirsch VM, Atanasov AG. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review. Biochem Pharmacol. 2014 Nov 1;92(1):73-89. doi: 10.1016/j.bcp.2014.07.018. Epub 2014 Jul 30. PMID: 25083916; PMCID: PMC4212005.

16. Dao, N.A., Vu, TD., Chu, DT. (2024). Bioinformatics in Drug Discovery. In: Singh, V., Kumar, A. (eds) Advances in Bioinformatics. Springer, Singapore. https://doi.org/10.1007/978-981-99-8401-5_11

17. Xuhua Xia, Bioinformatics and Drug Discovery, Current Topics in Medicinal Chemistry; Volume 17, Issue 15, Year 2017, .DOI: 10.2174/1568026617666161116143440 18. Somda, D., Wilson Kpordze, S., Jerpkorir, M., Chantelle Mahora, M., Wanjiru Ndungu, J., Wambui Kamau, S., … Elbasyouni, A. (2024). The Role of Bioinformatics in Drug Discovery: A Comprehensive Overview. IntechOpen. doi: 10.5772/intechopen.113712

19. Pinzi, L.; Rastelli, G. Molecular Docking: Shifting Paradigms in Drug Discovery. Int. J. Mol. Sci. 2019, 20, 4331. https://doi.org/10.3390/ijms20184331

20. Chaudhary KK, Mishra N (2016) A Review on Molecular Docking: Novel Tool for Drug Discovery. JSM Chem 4(3): 1029

21. Mohanraj, K., Karthikeyan, B.S., Vivek-Ananth, R.P. et al. IMPPAT: A curated database of Indian Medicinal Plants, Phytochemistry And Therapeutics. Sci Rep 8, 4329 (2018).

22. Kim S. Getting the most out of PubChem for virtual screening. Expert Opin Drug Discov. 2016 Sep;11(9):843-55. doi: 10.1080/17460441.2016.1216967. Epub 2016 Aug 5. PMID: 27454129; PMCID: PMC5045798.

23. Burley SK, Berman HM, Duarte JM, Feng Z, Flatt JW, Hudson BP, Lowe R, Peisach E, Piehl DW, Rose Y, Sali A, Sekharan M, Shao C, Vallat B, Voigt M, Westbrook JD, Young JY, Zardecki C. Protein Data Bank: A Comprehensive Review of 3D Structure Holdings and Worldwide Utilization by Researchers, Educators, and Students. Biomolecules. 2022 Oct 4;12(10):1425. doi: 10.3390/biom12101425. PMID: 36291635; PMCID: PMC9599165.

24. Bhagyashree L. Jejurikar, Sachin H. Rohane. Drug Designing in Discovery Studio. Asian J. Research Chem. 2021; 14(2):135-138. doi: 10.5958/0974-4150.2021.00025.0 Available on: https://www.ajrconline.org/AbstractView.aspx?PID=2021-14-2-8

25. Daina, A., Michielin, O. & Zoete, V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7, 42717 (2017). https://doi.org/10.1038/srep42717

26. Guoli Xiong, Zhenxing Wu, Jiacai Yi, Li Fu, Zhijiang Yang, Changyu Hsieh, Mingzhu Yin, Xiangxiang Zeng, Chengkun Wu, Aiping Lu, Xiang Chen, Tingjun Hou, Dongsheng Cao, ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties, Nucleic Acids Research, Volume 49, Issue W1, 2 July 2021, Pages W5–W14, https://doi.org/10.1093/nar/gkab255

27. Kar, S., & Leszczynski, J. (2020). Open access in silico tools to predict the ADMET profiling of drug candidates. Expert Opinion on Drug Discovery, 15(12), 1473–1487. https://doi.org/10.1080/17460441.2020.1798926

28.  https://doi.org/10.1093/bioinformatics/18.11.1548

29. Salim Bastaki; Diabetes mellitus and its treatment. International Journal of Diabetes and Metabolism 1 March 2005; 13 (3): 111–134. https://doi.org/10.1159/000497580

30. Miriam Cnop, Nils Welsh, Jean-Christophe Jonas, Anne Jörns, Sigurd Lenzen, Decio L. Eizirik; Mechanisms of Pancreatic β-Cell Death in Type 1 and Type 2 Diabetes: Many Differences, Few Similarities. Diabetes 1 December 2005; 54 (suppl_2): S97–S107. https://doi.org/10.2337/diabetes.54.suppl_2.S97

31. Confederat, L. U. M. I. N. I. Ț. A., et al. “Side effects induced by hypoglycaemic sulfonylureas to diabetic patients-a retrospective study.” Farmacia 64.5 (2016): 674-9.

32. Rizos, C., Elisaf, M., Mikhailidis, D., & Liberopoulos, E. (2008). How safe is the use of thiazolidinediones in clinical practice? Expert Opinion on Drug Safety, 8(1), 15–32. https://doi.org/10.1517/14740330802597821

33. Derosa G, Maffioli P. α-Glucosidase inhibitors and their use in clinical practice. Arch Med Sci. 2012 Nov 9;8(5):899-906. doi: 10.5114/aoms.2012.31621. Epub 2012 Nov 7. PMID: 23185202; PMCID: PMC3506243.

34. Katara, P. Role of bioinformatics and pharmacogenomics in drug discovery and development process. Netw Model Anal Health Inform Bioinforma 2, 225–230 (2013). https://doi.org/10.1007/s13721-013-0039-5

35. Lai X, Wang X, Hu Y, Su S, Li W, Li S. Editorial: Network Pharmacology and Traditional Medicine. Front Pharmacol. 2020 Aug 4;11:1194. doi: 10.3389/fphar.2020.01194. PMID: 32848794; PMCID: PMC7417929.

36. Periferakis, A.; Periferakis, K.; Badarau, I.A.; Petran, E.M.; Popa, D.C.; Caruntu, A.; Costache, R.S.; Scheau, C.; Caruntu, C.; Costache, D.O. Kaempferol: Antimicrobial Properties, Sources, Clinical, and Traditional Applications. Int. J. Mol. Sci. 2022, 23, 15054. https://doi.org/10.3390/ijms232315054

37. Chen M, Xiao J, El-Seedi HR, Woźniak KS, Daglia M, Little PJ, Weng J, Xu S. Kaempferol and atherosclerosis: From mechanism to medicine. Crit Rev Food Sci Nutr. 2024;64(8):2157-2175. doi: 10.1080/10408398.2022.2121261. Epub 2022 Sep 13. PMID: 36099317.

38. Imran, M.; Salehi, B.; Sharifi-Rad, J.; Aslam Gondal, T.; Saeed, F.; Imran, A.; Shahbaz, M.; Tsouh Fokou, P.V.; Umair Arshad, M.; Khan, H.; et al. Kaempferol: A Key Emphasis to Its Anticancer Potential. Molecules 2019, 24, 2277. https://doi.org/10.3390/molecules24122277

39. Alam, W.; Khan, H.; Shah, M.A.; Cauli, O.; Saso, L. Kaempferol as a Dietary Anti- Inflammatory Agent: Current Therapeutic Standing. Molecules 2020, 25, 4073. https://doi.org/10.3390/molecules25184073

40. Dong X, Zhou S, Nao J. Kaempferol as a therapeutic agent in Alzheimer’s disease: Evidence from preclinical studies. Ageing Res Rev. 2023 Jun;87:101910. doi: 10.1016/j.arr.2023.101910. Epub 2023 Mar 15. PMID: 36924572.

41. Dabeek WM, Marra MV. Dietary Quercetin and Kaempferol: Bioavailability and Potential Cardiovascular-Related Bioactivity in Humans. Nutrients. 2019 Sep 25;11(10):2288. doi: 10.3390/nu11102288. PMID: 31557798; PMCID: PMC6835347.

42. Yang Y, Chen Z, Zhao X, Xie H, Du L, Gao H, Xie C. Mechanisms of Kaempferol in the treatment of diabetes: A comprehensive and latest review. Front Endocrinol (Lausanne). 2022 Sep 7;13:990299. doi: 10.3389/fendo.2022.990299. PMID: 36157449; PMCID: PMC9490412.

43. Li, Y., Mai, Y., Qiu, X. et al. Effect of long-term treatment of Carvacrol on glucose metabolism in Streptozotocin-induced diabetic mice. BMC Complement Med Ther 20, 142 (2020). https://doi.org/10.1186/s12906-020-02937-0

44. Hoca, M., Becer, E., & Vatansever, H. S. (2023). Carvacrol is potential molecule for diabetes treatment. Archives of Physiology and Biochemistry, 130(6), 823–830. https://doi.org/10.1080/13813455.2023.2288537

Ahead of Print Subscription Original Research
Volume 03
02
Received 19/05/2025
Accepted 24/09/2025
Published 26/09/2025
Publication Time 130 Days
269

Login


My IP

PlumX Metrics